DelveInsight’s latest report, “HER2+ Gastric Cancer – Market Insight, Epidemiology And Market Forecast – 2034”, provides an in-depth analysis of the evolving treatment landscape, epidemiological trends, and market dynamics across the 7MM. The report highlights advancements in HER2-targeted therapies, immunotherapy combinations, and antibody-drug conjugates (ADCs) that are poised to transform patient outcomes in this aggressive cancer subtype.
Download the report to understand which factors are driving the HER2 Positive Gastric Cancer therapeutic market @ HER2 Positive Gastric Cancer Market Trends.
The gastric cancer incidence varies considerably across different geographic regions, with Eastern Asian countries, including Japan, reporting the highest incidence rates. The US also accounts for a notable proportion of gastric cancer cases, representing 1.5% of all new cancer diagnoses each year.
As per DelveInsight’s estimates, the HER2+ gastric cancer market is projected to grow significantly from 2024 to 2034. This growth is driven by a rising incidence, improved diagnostic protocols, and expanding therapeutic options. Several pipeline drugs for HER2+ gastric cancer, including Evorpacept (ALX Oncology), Zanidatamab (Jazz Pharmaceuticals), IAM1363 (Iambic Therapeutics), ELVN 002 (Enliven Therapeutics), ARX788 (Ambrx), and Rilvegostomig (AstraZeneca), are in development.
Discover evolving trends in HER2+ Gastric Cancer patient pool forecasts @ HER2+ Gastric Cancer Epidemiology Analysis.
Recent Developments:
-
The DESTINY-Gastric04 trial results were presented at the 2025 ASCO Annual Meeting, showing that trastuzumab deruxtecan can help people with advanced HER2-positive gastric cancers that have progressed during first-line treatment live about 3 months longer. This is the first phase 3 clinical trial to directly compare trastuzumab deruxtecan against paclitaxel with ramucirumab in the second-line setting.
-
The DESTINY-Gastric04 phase 3 clinical trial results were published in July 2025, demonstrating significant survival benefits for trastuzumab deruxtecan (T-DXd) in the second-line setting. The trial showed a median overall survival of 14.7 months with T-DXd compared to 11.4 months with ramucirumab plus paclitaxel, representing a 30% reduction in the risk of death. This establishes trastuzumab deruxtecan as a new standard of care for second-line treatment in HER2-positive metastatic gastric cancer
-
Henlius presented updated phase 2 results for their novel anti-HER2 monoclonal antibody HLX22 with over two years of follow-up data in ASCO 2025. The company also unveiled the design for the international multicenter phase 3 clinical trial (HLX22-GC-301), which features a head-to-head comparison with the first-line standard of care therapy (trastuzumab + chemotherapy ± pembrolizumab).
-
In April 2025, Henlius initiated a phase 2 clinical trial (HLX22-BC201) of HLX22 in combination with trastuzumab deruxtecan for the treatment of HER2-low, hormone receptor-positive locally advanced or metastatic breast cancer, completing first patient dosing in China.
-
In March 2025, the FDA granted traditional approval to pembrolizumab (Keytruda) with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 (CPS ≥1).
These recent developments highlight the momentum in the field. Learn more about the evolving trends in HER2+ Gastric Cancer treatment market @ HER2+ Gastric Cancer Recent Developments.
Additionally, recent therapy approvals such as ENHERTU (Daiichi Sankyo and AstraZeneca), OPDIVO (Bristol Myers Squibb), trastuzumab (Roche), KEYTRUDA (Merck & Co., Inc.), and AIDIXI (RemeGen) are further fueling the market growth. The FDA has also approved HLX02 (Henlius Biotech), a HERCEPTIN biosimilar, as an adjuvant therapy for patients with HER2-overexpressing metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Despite the active landscape of HER2+ gastric cancer therapeutics, there is a continued need for the development of novel drugs that are more effective and less toxic. DelveInsight’s leading oncology consultant notes, “One of the major challenges in treating HER2-positive gastric cancer is the development of resistance to existing therapies. It is indicated that up to 70% of patients who progress after the initial trastuzumab treatment may lose HER2 expression or acquire genetic alterations that render them resistant to further anti-HER2 therapies.” This underscores the potential impact of emerging therapies in revolutionizing HER2-positive gastric cancer treatment.
In summary, the factors mentioned above are contributing to the significant expansion of the HER2+ gastric cancer market, suggesting a future where improved screening, innovative drug delivery systems, and novel therapies will transform the management of a disease that continues to challenge clinicians and patients alike.
Table of Contents
1. Key Insights
2. Executive Summary of HER2+ Gastric Cancer
3. HER2+ Gastric Cancer Competitive Intelligence Analysis
4. HER2+ Gastric Cancer: Market Overview at a Glance
5. HER2+ Gastric Cancer: Disease Background and Overview
6. Patient Journey
7. HER2+ Gastric Cancer Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. HER2+ Gastric Cancer Unmet Needs
10. Key Endpoints of HER2+ Gastric Cancer Treatment
11. HER2+ Gastric Cancer Marketed Products
12. HER2+ Gastric Cancer Emerging Therapies
13. HER2+ Gastric Cancer: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of HER2+ Gastric Cancer
17. KOL Views
18. HER2+ Gastric Cancer Market Drivers
19. HER2+ Gastric Cancer Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Related Reports
HER2 Positive Gastric Cancer Pipeline Insight
HER2 Positive Gastric Cancer Pipeline Insight provides comprehensive insights about the HER2 Positive Gastric Cancer pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the HER2 Positive Gastric Cancer companies, including Jiangsu HengRui Medicine Co., Ltd., Pieris Pharmaceuticals, BioInvent International, Daiichi Sankyo|AstraZeneca, Shanghai JMT-Bio Inc., Acepodia Biotech, Inc., Klus Pharma Inc., Carisma Therapeutics Inc, Novartis Pharmaceuticals, Celularity Incorporated, Hoffmann-La Roche, DualityBio Inc., Shanghai Miracogen Inc., Bavarian Nordic, among others.
About DelveInsight
DelveInsight is a leading business Healthcare consultancy and market research firm specializing in life sciences. It assists pharmaceutical companies by offering comprehensive, end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services